Gorusu et al. [13] confirmed that deletions of the ABL1 or BCL locus were more prevalent in variant translocation CML cases and indicated statistically worse therapeutic responses (p<0.04) and outcomes. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.